Difference between revisions of "Juvenile myelomonocytic leukemia"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m |
||
| Line 14: | Line 14: | ||
==Azacitidine monotherapy {{#subobject:3235e3|Regimen=1}}== | ==Azacitidine monotherapy {{#subobject:3235e3|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:bad5a2|Variant=1}}=== | ===Regimen {{#subobject:bad5a2|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 26: | Line 26: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Azacitidine (Vidaza)]] 75 mg/m<sup>2</sup> IV once per day on days 1 to 7 | *[[Azacitidine (Vidaza)]] 75 mg/m<sup>2</sup> IV once per day on days 1 to 7 | ||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''AZA-JMML-001:''' Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. [https://doi.org/10.1182/bloodadvances.2020004144 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34297046/ PubMed] NCT02447666 | # '''AZA-JMML-001:''' Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. [https://doi.org/10.1182/bloodadvances.2020004144 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34297046/ PubMed] NCT02447666 | ||
Revision as of 14:05, 9 March 2023
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, <20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666